officially retracts the paper entitled, “MiR-181a Promotes Apoptosis and Reduces Cisplatin Resistance by Inhibiting Osteopontin in Cervical Cancer Cells,” by Xiaofei Xu, Xiaofei Jiang, Liping Chen, Yu Zhao, Zhihua Huang, Huifang Zhou, and Mingqing Shi (Cancer Biother Radiopharm. 2019;34(9)559–565; doi: 10.1089/cbr.2019.2858) due to the discovery that the paper was submitted from a paper mill. This is a violation of the journal's standard protocols and is considered an infraction against the rigorous standards of scientific publishing.
The Editor and Publisher of Cancer Biotherapy and Radiopharmaceuticals are committed to preserving the scientific literature and the community it serves, and does not tolerate any improprieties.
Get full access to this article
View all access options for this article.
References
1.
SchiffmanM. Cervical cancer screening: Epidemiology as the necessary but not sufficient basis of public health practice. Prev Med, 2017; 98:3.
2.
PimpleS, MishraG, ShastriS. Global strategies for cervical cancer prevention. Curr Opin Obstet Gynecol, 2016; 28:4.
3.
Duenas-GonzalezA, CampbellS. Global strategies for the treatment of early-stage and advanced cervical cancer. Curr Opin Obstet Gynecol, 2016; 28:11.
4.
GuX, GaoXS, MaM, et al.Prognostic significance of osteopontin expression in gastric cancer: A meta-analysis. Oncotarget, 2016; 7:69666.
5.
HuangRH, QuanYJ, ChenJH, et al.Osteopontin promotes cell migration and invasion, and inhibits apoptosis and autophagy in colorectal cancer by activating the p38 MAPK signaling pathway. Cell Physiol Biochem, 2017; 41:1851.
6.
KerenidiT, KazakouAP, LadaM, et al.Clinical significance of circulating osteopontin levels in patients with lung cancer and correlation with VEGF and MMP-9. Cancer Invest, 2016; 34:385.
7.
PioGM, XiaY, PiasecznyMM, et al.Soluble bone-derived osteopontin promotes migration and stem-like behavior of breast cancer cells. PLoS One, 2017; 12:e0177640.
8.
DingK, FanL, ChenS, et al.Overexpression of osteopontin promotes resistance to cisplatin treatment in HCC. Oncol Rep, 2015; 34:3297.
9.
LuoSD, ChenYJ, LiuCT, et al.Osteopontin involves cisplatin resistance and poor prognosis in oral squamous cell carcinoma. Biomed Res Int, 2015; 2015:508587.
10.
NakamuraKD, TilliTM, WanderleyJL, et al.Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells. Tumour Biol, 2016; 37:2655.
11.
FuQ, YangF, XiangT, et al.A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy. Sci Rep, 2018; 8:7933.
12.
LiaoX, ZhuG, HuangR, et al.Identification of potential prognostic microRNA biomarkers for predicting survival in patients with hepatocellular carcinoma. Cancer Manag Res, 2018; 10:787.
13.
YangM, ZhaiX, GeT, et al.miR-181a-5p promotes proliferation and invasion and inhibits apoptosis of cervical cancer cells via regulating inositol polyphosphate-5-phosphatase A (INPP5A). Oncol Res, 2018; 26:703.
14.
LuoC, QiuJ. miR-181a inhibits cervical cancer development via downregulating GRP78. Oncol Res, 2017; 25:1341.
15.
ChenY, KeG, HanD, et al.MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD. Exp Cell Res, 2014; 320:12.
16.
ChatterjeeS, ChattopadhyayA, SamantaL, et al.HPV and cervical cancer epidemiology—Current status of HPV vaccination in India. Asian Pac J Cancer Prev, 2016; 17:3663.
17.
LuckettR, FeldmanS. Will HPV vaccination affect cervical cancer morbidity and mortality world-wide?. Hum Vaccin Immunother, 2016; 12:1373.
18.
Hugo de AlmeidaV, GuimaraesIDS, AlmendraLR, et al.Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer. Oncotarget, 2018; 9:30594.
19.
LachkarB, MinaguchiT, AkiyamaA, et al.Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin. Medicine, 2018; 97:e11392.
20.
AokiY, OchiaiK, LimS, et al.Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer. Br J Cancer, 2018; 119:530–537.
21.
LuoC, FanW, JiangY, et al.Glucose-related protein 78 expression and its effects on cisplatin-resistance in cervical cancer. Med Sci Monit, 2018; 24:2197.
22.
MeiY, PengC, LiuYB, et al.Silencing RIF1 decreases cell growth, migration and increases cisplatin sensitivity of human cervical cancer cells. Oncotarget, 2017; 8:107044–107051.
23.
PotocnjakI, GobinI, DomitrovicR. Carvacrol induces cytotoxicity in human cervical cancer cells but causes cisplatin resistance: Involvement of MEK-ERK activation. Phytother Res, 2018; 32:1090.
24.
WeiR, WongJPC, KwokHF. Osteopontin—A promising biomarker for cancer therapy. J Cancer, 2017; 8:2173.
25.
KarpinskyG, FatygaA, KrawczykMA, et al.Osteopontin: Its potential role in cancer of children and young adults. Biomark Med, 2017; 11:389.
26.
AksoyA, ArtasG, SevindikOG. Predictive value of stathmin-1 and osteopontin expression for taxan resistance in metastatic castrate-resistant prostate cancer. Pak J Med Sci, 2017; 33:560.
27.
KamalA, DarwishRK, SaadS, et al.Association of osteopontin gene polymorphisms with colorectal cancer. Cancer Invest, 2017; 35:71.
28.
WeiR, WongJPC, LyuP, et al.In vitro and clinical data analysis of Osteopontin as a prognostic indicator in colorectal cancer. J Cell Mol Med, 2018; 22:4097–4105.
29.
HaoC, CuiY, OwenS, et al.Human osteopontin: Potential clinical applications in cancer (Review). Int J Mol Med, 2017; 39:1327.
30.
LeF, LuoP, YangQO, et al.MiR-181a promotes growth of thyroid cancer cells by targeting tumor suppressor RB1. Eur Rev Med Pharmacol Sci, 2017; 21:5638.
31.
LinY, ZhaoJ, WangH, et al.miR-181a modulates proliferation, migration and autophagy in AGS gastric cancer cells and downregulates MTMR3. Mol Med Rep, 2017; 15:2451.
32.
PingW, GaoY, FanX, et al.MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7. Biochem Biophys Res Commun, 2018; 495:2482.
33.
YangC, TabatabaeiSN, RuanX, et al.The dual regulatory role of MiR-181a in breast cancer. Cell Physiol Biochem, 2017; 44:843.
34.
LeungDT, LimPL, CheungTH, et al.Osteopontin fragments with intact thrombin-sensitive site circulate in cervical cancer patients. PLoS One, 2016; 11:e0160412.
35.
SongJY, LeeJK, LeeNW, et al.Osteopontin expression correlates with invasiveness in cervical cancer. Aust N Z J Obstet Gynaecol, 2009; 49:434.
